Prognostic Genomic Tests
Breast Cancer
Key Facts
About Eurobio Scientific
Eurobio Scientific is a French specialty diagnostics leader that develops, manufactures, and commercializes a broad portfolio of molecular diagnostic tests and life science products. Its core business segments include oncology (with prognostic genomic tests), infectious diseases, transplantation, and life sciences (cell culture media, ELISA kits, quality controls). The company has established itself as a significant player in the European diagnostics market through both proprietary innovation and strategic partnerships, serving clinical laboratories and research institutions globally.
View full company profileAbout Eurobio Scientific
Eurobio Scientific is a French specialty diagnostics leader that develops, manufactures, and commercializes a broad portfolio of molecular diagnostic tests and life science products. Its core business segments include oncology (with prognostic genomic tests), infectious diseases, transplantation, and life sciences (cell culture media, ELISA kits, quality controls). The company has established itself as a significant player in the European diagnostics market through both proprietary innovation and strategic partnerships, serving clinical laboratories and research institutions globally.
View full company profileOther Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Novartis | Acquisition |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Ogivri (Trastuzumab) | Biocon | Approved |
| Tamoxifen | Natco Pharma | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |